Stifel lowered the firm’s price target on AbCellera (ABCL) to $10 from $12 and keeps a Buy rating on the shares. The firm believes FY25 “marks an important inflection point” as the company completes the transition from a discovery-focused partner to a fully-integrated drug development company, the analyst tells investors. The firm’s updated estimates mostly reflect reduced partnership-derived revenue and revised financing assumptions, the analyst noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue